Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ANTX | An2 Therapeutics | $6.16 | $3.31 | 115.97% | 26.1M | $78M | $1.00$6.18 |
| HIMZ | Tidal Trust II - Defiance Daily Target 2x Long Hims ETF | $2.04 | $0.92 | 81.70% | 120.3M | - | $0.88$55.77 |
| DTCK | Davis Commodities | $2.31 | $0.88 | 61.54% | 22.7M | $39M | $1.32$137.80 |
| TURB | Turbo Energy | $5.74 | $1.96 | 51.72% | 18.1M | $42M | $0.57$20.45 |
| XENE | Xenon Pharmaceuticals | $61.91 | $19.97 | 47.62% | 470K | $3.5B | $26.74$62.40 |
| HIMS | Hims & Hers Health | $22.17 | $6.43 | 40.85% | 4.7M | $3.6B | $13.74$70.43 |
| RLMD | Relmada Therapeutics | $6.02 | $1.57 | 35.17% | 32M | $326M | $0.24$6.52 |
| ATRA | Atara Biotherapeutics | $6.79 | $1.62 | 31.34% | 49.1K | $37M | $3.92$19.15 |
| CAMP | Camp4 Therapeutics | $5.49 | $1.29 | 30.71% | 60.3K | $218M | $1.31$7.31 |
| RNAC | Cartesian Therapeutics | $8.90 | $2.05 | 29.93% | 9.4K | $178M | $5.98$18.80 |
| NERV | Minerva Neurosciences | $7.55 | $1.54 | 25.68% | 233.1K | $260M | $1.15$12.46 |
| DNTH | Dianthus Therapeutics | $81.48 | $16.28 | 24.96% | 94.3K | $2.8B | $13.37$84.78 |
| AGCC | Agencia Comercial Spirits | $22.43 | $4.32 | 23.85% | 52K | $623M | $3.66$22.88 |
| EDIT | Editas Medicine | $2.46 | $0.46 | 23.00% | 113.9K | $195M | $0.91$4.54 |
| PLYX | Polaryx Therapeutics | $3.37 | $0.63 | 22.81% | 517.8K | $130M | $2.20$48.91 |
| QURE | uniQure | $17.40 | $3.13 | 21.93% | 408.6K | $879M | $7.76$71.50 |
| LSTA | Lisata Therapeutics | $5.04 | $0.86 | 20.45% | 340.8K | $37M | $1.81$5.06 |
| RGNX | Regenxbio | $10.41 | $1.76 | 20.35% | 65.5K | $438M | $5.04$16.19 |
| CCCC | C4 Therapeutics | $3.59 | $0.55 | 17.93% | 99.5K | $297M | $1.09$3.65 |
| KC | Kingsoft Cloud | $14.13 | $2.14 | 17.85% | 89.5K | $3.5B | $10.29$19.57 |
| BEG | Themes ETF Trust - Leverage Shares 2x Long Be Daily ETF | $30.76 | $4.62 | 17.67% | 31.2K | - | $10.89$50.61 |
| DDD | 3D Systems | $2.31 | $0.35 | 17.60% | 3.9M | $252M | $1.32$3.80 |
| VRTL | GraniteShares ETF Trust - GraniteShares 2x Long Vrt Daily ETF | $115.71 | $16.81 | 17.00% | 150.7K | - | $7.57$119.89 |
| JFB | Jfb Construction | $19.00 | $2.56 | 15.57% | 2.1K | $104M | $3.42$35.10 |
| NBTX | Nanobiotix | $39.24 | $5.25 | 15.45% | 1.9K | $1.6B | $2.95$39.65 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $3.98 | $0.51 | 14.70% | 24.9M | - | $0.95$20.92 |
| TAOX | Tao Synergies | $4.55 | $0.58 | 14.61% | 64.7K | $30M | $1.84$11.98 |
| RCKT | Rocket Pharmaceuticals | $5.05 | $0.64 | 14.51% | 88.3K | $479M | $2.19$8.91 |
| CRBP | Corbus Pharmaceuticals | $9.07 | $1.06 | 13.23% | 7.2K | $141M | $4.64$20.56 |
| PURR | Hyperliquid Strategies | $4.86 | $0.53 | 12.13% | 4.2M | $537M | $3.01$5.78 |
Related Articles
Featured Article
Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?
Geoffrey Seiler|Mar 9, 2026
Hims & Hers stock traded more than 40% higher after the deal was announced.
Hims & Hers Stock Pops 40%: Everything You Need to Know
Travis Hoium|Mar 9, 2026
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back?
Geoffrey Seiler|Feb 27, 2026
The company is looking toward international markets to boost its growth.
Hims & Hers HUGE Acquisition News!
Travis Hoium|Feb 19, 2026
Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.
Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?
Bram Berkowitz|Feb 9, 2026
Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
Selena Maranjian|Nov 24, 2025
It has grown wildly, and it could keep growing.
